Summit Therapeutics PLC (NASDAQ:SMMT) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eighteen analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $28.38.

Several equities analysts have recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Sunday. Wall Street Zen upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 5th. Guggenheim restated a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Summit Therapeutics in a report on Tuesday, September 22nd. Finally, Leerink Partners upgraded shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and boosted their price target for the stock from $12.00 to $13.00 in a report on Wednesday, August 12th.

Check Out Our Latest Report on Summit Therapeutics

Institutional Investors Weigh In On Summit Therapeutics

Several hedge funds have recently made changes to their positions in the business. Fifth Third Bancorp grew its stake in shares of Summit Therapeutics by 24.4% during the 1st quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock valued at $71,000 after buying an additional 732 shares during the period. Tidal Investments LLC raised its position in shares of Summit Therapeutics by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock worth $1,764,000 after buying an additional 783 shares during the period. Russell Investments Group Ltd. raised its position in shares of Summit Therapeutics by 2.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock worth $722,000 after buying an additional 1,021 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of Summit Therapeutics by 1.1% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock worth $1,611,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Summit Therapeutics by 61.7% in the third quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock valued at $46,000 after acquiring an additional 1,029 shares during the last quarter. Institutional investors and hedge funds own 4.61% of the company’s stock.

Key Stories Impacting Summit Therapeutics

These are some of the SMMT stories that stood out recently:

  • Neutral Sentiment: Commentary describes first-line ivonescimab data as a future catalyst, while noting difficulties in the second-line setting. The data could help shape the investment outlook, but its results are not yet known. Seeking Alpha analysis
  • Neutral Sentiment: Barclays lowered its price target from $20 to $18 and kept an Equal Weight rating. Separately, call-option trading surged, indicating unusually active but directionally uncertain investor positioning. Barclays rating
  • Negative Sentiment: The FDA issued a Complete Response Letter and declined to approve ivonescimab for lung cancer. Reports say the agency found the overall-survival evidence insufficient despite positive progression-free-survival results. The decision clouds the drug’s regulatory path and contributed to shares falling to a 52-week low. Reuters report Zacks report

Summit Therapeutics Trading Down 9.7%

Shares of NASDAQ SMMT opened at $10.67 on Wednesday. The business’s fifty day simple moving average is $16.16 and its 200-day simple moving average is $16.09. Summit Therapeutics has a 12-month low of $10.53 and a 12-month high of $29.23.

Summit Therapeutics Company Profile

(Get Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.

Featured Stories

Analyst Recommendations for Summit Therapeutics (NASDAQ:SMMT)

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.